Mitchell E. Gross
YOU?
Author Swipe
View article: EphB4-ephrin-B2 are targets in castration resistant prostate cancer
EphB4-ephrin-B2 are targets in castration resistant prostate cancer Open
Background PI3K pathway activation is a common and early event in prostate cancer, from loss of function mutations in PTEN , or activating mutations in PIK3Ca or AKT leading to constitutive activation, induction of growth factor-receptors …
View article: Improved quantitative parameter estimation for prostate T2 relaxometry using convolutional neural networks
Improved quantitative parameter estimation for prostate T2 relaxometry using convolutional neural networks Open
Objective Quantitative parameter mapping conventionally relies on curve fitting techniques to estimate parameters from magnetic resonance image series. This study compares conventional curve fitting techniques to methods using neural netwo…
View article: A-229 Immune Biomarkers Associated with COVID-19 Disease Severity in an Urban, Hospitalized Population
A-229 Immune Biomarkers Associated with COVID-19 Disease Severity in an Urban, Hospitalized Population Open
Background We sought to identify immune biomarkers associated with severe Coronavirus disease 2019 (COVID-19) in patients admitted to a large public county hospital during the early phase of the SARS-CoV-2 pandemic. We hypothesized that we…
View article: Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics
Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics Open
Bi-directional crosstalk between the tumor and the tumor microenvironment (TME) has been shown to increase the rate of tumor evolution and to play a key role in neoplastic progression, therapeutic resistance, and a patient’s overall surviv…
View article: Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration
Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration Open
Monoamine oxidases (MAOA/MAOB) are enzymes known for their role in neurotransmitter regulation in the central nervous system (CNS). Irreversible and non-selective MAO inhibitors (MAOi's) were the first class of antidepressants, thus subseq…
View article: Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population
Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population Open
Our results confirm the known adverse association of BMI on COVID-19 severity and suggest that IP-10 and SARS-CoV-2 antibodies could be useful to identify patients most likely to experience the most severe forms of the disease.
View article: Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
Clinical oncology is hampered by lack of tools to accurately assess a patient's response to pathway-targeted therapies. Serum and tumor cell surface proteins whose abundance, or change in abundance in response to therapy, differentiates pa…
View article: Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 47KB, Protein Identification for Solid Phase Extraction of Glycoproteins (SPEG)with 16 hours of gefitinib treatment.
View article: Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonstrate a correlation to gefitinib sensitivity. Non-treated NSCLC lysates, synchronized by serum starvation for 16 hours, were generated and assa…
View article: Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 83KB.
View article: Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 299KB, Protein level changes associated with gefitinib treatment in NSCLC tissue.
View article: Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 299KB, Protein level changes associated with gefitinib treatment in NSCLC tissue.
View article: Supplementary Table 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Table 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 5465KB, Quantitation tables for proteins identified and quantified.
View article: Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 47KB, Protein Identification for Solid Phase Extraction of Glycoproteins (SPEG)with 16 hours of gefitinib treatment.
View article: Supplementary Table 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Table 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 3.66MB, Proteomic data table. Tabular list of proteomic data from the 2 hr and 16 hour gefitinib treated experiments. Whole cell lysate (WCL), cell-surface (SUR), and SPEG/GC.
View article: Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 83KB.
View article: Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 321KB, Protein levels changes associated with EGFR targeted and non-EGFR targeted drugs.
View article: Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 321KB, Protein levels changes associated with EGFR targeted and non-EGFR targeted drugs.
View article: Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
Clinical oncology is hampered by lack of tools to accurately assess a patient's response to pathway-targeted therapies. Serum and tumor cell surface proteins whose abundance, or change in abundance in response to therapy, differentiates pa…
View article: Supplementary Figure 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 140KB, Bioinformatic characterization of gefitinib induced protein level changes.
View article: Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 4 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 131KB, Basal levels protein biomarkers. Basal levels of EpCAM, ELAVL1, and CBFB demonstrate a correlation to gefitinib sensitivity. Non-treated NSCLC lysates, synchronized by serum starvation for 16 hours, were generated and assa…
View article: Supplementary Table 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Table 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 5465KB, Quantitation tables for proteins identified and quantified.
View article: Supplementary Table 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Table 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 3.66MB, Proteomic data table. Tabular list of proteomic data from the 2 hr and 16 hour gefitinib treated experiments. Whole cell lysate (WCL), cell-surface (SUR), and SPEG/GC.
View article: Supplementary Figure 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
Supplementary Figure 1 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition Open
PDF file, 140KB, Bioinformatic characterization of gefitinib induced protein level changes.
View article: Supplementary Table 1 from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
Supplementary Table 1 from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer Open
PDF file - 65K, Schedule of assessments.
View article: Data from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
Data from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer Open
Purpose: The androgen receptor pathway remains active in men with prostate cancer whose disease has progressed following surgical or medical castration. Orteronel (TAK-700) is an investigational, oral, nonsteroidal, selective, reversible i…
View article: Supplementary Table 1 from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
Supplementary Table 1 from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer Open
PDF file - 65K, Schedule of assessments.
View article: Data from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer
Data from Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer Open
Purpose: The androgen receptor pathway remains active in men with prostate cancer whose disease has progressed following surgical or medical castration. Orteronel (TAK-700) is an investigational, oral, nonsteroidal, selective, reversible i…
View article: Improved Quantitative Parameter Estimation for Prostate T2 Relaxometry using Convolutional Neural Networks
Improved Quantitative Parameter Estimation for Prostate T2 Relaxometry using Convolutional Neural Networks Open
This work seeks to evaluate multiple methods for quantitative parameter estimation from standard T 2 mapping acquisitions in the prostate. The T 2 estimation performance of methods based on neural networks (NN) was quantitatively compared …
View article: Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial
Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial Open
Purpose: Prostate cancer survivors (PCS) receive androgen deprivation therapy (ADT) as treatment for recurrent cancer, yet ADT is associated with loss of skeletal muscle and physical function. Resistance training can counter both muscle an…